Ortega CMJ, Ahumada ZSN, Díaz GE, Rodríguez WF

Language: Spanish
References: 28
Page: 246-250
PDF size: 164.82 Kb.

ABSTRACT

Infections caused by hepatitis B virus (HBV) and hepatitis C virus (HCV), are global health issues and a serious risk associated to transfusional medicine; especially being one of the most important causes of liver damage in Mexico. Objective: To determine the prevalence of HBV and HCV in blood donors in Hospital Angeles Pedregal in a time lapse of 19 months. Material and methods: Retrospective and descriptive study carried out between the 1st of January 2018 and the 31st of July 2019, which included 5,705 donors. Results: Of 4,030 selected cases, 30.72% were female and 69.28% were male. We identified 22 altruistic donors and 4,008 for replacement of blood products. Global seroprevalence observed in our population was 0.27% for HCV and 0.04% for HBV. HVC infection was more frequent in females between 45 to 65 years, with three cases. Conclusions: A low prevalence of HBV and HVC infection was found, being 0.27% and 0.04%, respectively, HCV prevalence was found to be 5.5 times greater than HBV. These findings are probably explained because blood donors generally are healthy.

REFERENCES

1. Marrón-Peña M. Historia de la transfusión sanguínea. Rev Mex Anest. 2017; 40: 233-238.

2. Kim MJ, Park Q, Min HK, Kim HO. Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010. BMC Infect Dis. 2012; 12: 160. doi: 10.1186/ 1471-2334-12-160.

3. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386 (10003): 1546-1555.

4. World Health Organization. Global hepatitis report. Geneva: World Health Organization; 2017.

5. Calleja PJ, Llop HE, Ruiz MM, De la Revilla NJ, Calvo BE, Pons RF et al. Prevalence of viral hepatitis (Band C) serological warkers in healthy working population. Rev Esp Enferm Dig. 2013; 105: 249-254.

6. Cobb B, Pockros PJ, Vilchez RA, Vierling JM. HCV RNA viral load assessments in the era of direct-acting antivirals. Am J Gastroenterol. 2013; 108: 471-475.

7. World Health Organization. Hepatitis B. Fact Sheet N° 204. [sede web]. [actualizada 27 julio 2020] Disponible en: http://www.who.int/mediacentre/factsheets/fs204/en/.

8. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014; 384: 2053-2063.

9. Sanchez LV, Maldonado M, Bastidas-Ramirez BE, Norder H, Panduro A. Genotypes and S-gene variability of Mexican hepatitis B virus strains. J Med Virol. 2002; 68: 24-32.

10. World Health Organization. Introduction of hepatitis B vaccine into childhood immunization services: management guidelines, including information for health workers and parents [sede web]. Geneva: WHO, Department of Vaccines and Biologicals; 2001. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/66957/WHO_V-B_01.31_eng.pdf?sequence=1&isAllowed=y

11. Panduro A, Roman S, Khan A, Tanaka Y, Kurbanov F, Martinez-Lopez E et al. Molecular epidemiology of hepatitis C virus genotypes in West Mexico. Virus Research. 2010; 151: 19-25.

12. Jimenez-Mendez R, Uribe-Salas F, Lopez-Guillen P, Cisneros-Garza L, Castañeda-Hernandez G. Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico. Ann Hepatol. 2010; 9: 33-39.

13. Gardenier D, Kwong J, Olson M, Epstein R. Epidemiology, screening, and pretreatment evaluation of the patient with chronic hepatitis C infection. J Nurse Pract. 2015; 11: 109-115.

14. Halabe ChJ, Angulo VF. Hepatitis viral. Rev Fac Med UNAM. 2000; 43: 90-100.

15. Rivero-Jiménez RA. Transmisión de infecciones virales por la transfusión de sangre. Rev Cubana Hematol Inmunol Hemoter. 2006; 22.

16. World Health Organization. Los datos más recientes ponen de relieve la necesidad de actuar urgentemente a nivel mundial contra las hepatitis [sede web]. Ginebra: Organización Mundial de la Salud. [actualizado 21 Abril 2017]. Disponible en: https://www.who.int/es/news-room/detail/21-04-2017-new-hepatitis-data-highlight-need-for-urgent-global-response.

17. Secretaría de Salud. Anuario de morbilidad 1984-2015. Estados Unidos Mexicanos: SUIVE/DGE Secretaría de Salud; 2015.

18. Abbott. Manual de operaciones del sistema Architect [sede web]. Abbott Laboratories. 2013.

19. Abbott. Manual de operaciones del sistema Architect [sede web]. Abbott Laboratories Anti HCV. 2014.

20. Abbott. Manual de operaciones del sistema Architect [sede web]. Abbott Laboratories HBsAg Qualitative II. 2013.

21. Abbott. Manual de operaciones del sistema Architect [sede web]. Abbott Laboratories Anti-HBc II. 2015.

22. Hernández-Pérez RE, Frías-Salcedo JA, Del Ángel-Guevara O. Seroprevalencia de anticuerpos contra el virus de la hepatitis C en donadores de sangre del Hospital Central Militar. Salud Publica Mex. 1994; 36: 538-540.

23. Álvarez-Muñoz MT, Bustamante-Calvillo ME. Hepatitis B y Delta: prevalencia de marcadores cero epidemiológicos en donadores de sangre voluntarios y su grupo familiar. Gac Med Mex. 1991; 127: 399-404.

24. Méndez-Sánchez N, Baptista-González H, Sánchez-Gómez RH, Bordes-Aznar J, Uribe-Esquivel M. Prevalencia de hepatitis B y C en un Hospital de Tercer Nivel de la Ciudad de México. Salud Pública de México. 1999; 41: 6.

25. Organización Panamericana de la Salud. Suministro de sangre para transfusiones en los países de Latinoamérica del Caribe. OPS; 2017.

26. Rivera-López MRF, Zavala-Méndez C, Arenas-Esqueda A. Prevalencia de seropositividad para VIH, hepatitis B y C en donadores de sangre. Gac Méd Méx. 2004; 140 (6): 657-660.

27. Souto-Meiriño CA, Simón-Domínguez J, Pulido-Priego MA, Hernández-Pérez A, García-Hernández IC, Del Río-Chiriboga CA. Prevalencia de marcadores para hepatitis A, B y C en un hospital de México. Salud Publica de México. 1994; 36 (3): 257-262.

28. Carreto-Vélez MA, Carrada-Bravo T, Martínez-Magdaleno A. Seroprevalencia de VHB, VHC y VIH en donadores de sangre en Irapuato, México. Salud Pública de México. 2003; 45 (S5): 690-693.